1. Market Research
  2. > Acrux Limited – Product Pipeline Review – 2013

Acrux Limited – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 41 pages

Acrux Limited – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Acrux Limited - Product Pipeline Review - 2013” provides data on the Acrux Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Acrux Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Acrux Limited and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Acrux Limited - Brief Acrux Limited overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Acrux Limited human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Acrux Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Acrux Limited’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Acrux Limited’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Acrux Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Acrux Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Acrux Limited.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Acrux Limited and identify potential opportunities in those areas.

Table Of Contents

Acrux Limited - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Acrux Limited Snapshot 5
Acrux Limited Overview 5
Key Information 5
Key Facts 5
Acrux Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Acrux Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Acrux Limited - Pipeline Products Glance 11
Acrux Limited - Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Acrux Limited Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Acrux Limited - Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Acrux Limited - Drug Profiles 15
(estradiol + progesterone ) 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
estradiol 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Nestorone 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Nicotine 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
NSAID Transdermal System 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
testosterone 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
Acrux Limited - Pipeline Products by Route of Administration 22
Acrux Limited - Pipeline Products By Mechanism of Action 23
Acrux Limited - Company Statement 25
Acrux Limited - Locations And Subsidiaries 26
Head Office 26
Other Locations and Subsidiaries 26
Financial Deals Landscape 27
Acrux Limited, Deals Summary 27
Acrux Limited, Pharmaceuticals and Healthcare, Deal Details 28
Partnerships 28
KV Pharma Enters Into Licensing Agreement With Acrux 28
Acrux Enters Into A Co-Marketing Agreement With HRA Pharma 29
Acrux Enters Into Co-Marketing Agreement With Vifor Pharma 31
Acrux Enters Into Co-Marketing Agreement With Aspen Pharmacare 32
Licensing Agreements 33
KV Pharma Expands Licensing Agreement With Acrux 33
Acrux Enters Into Licensing Agreement With Aspen Pharmacare 34
Acrux Enters Into Licensing Agreement With Organon BioSciences For Spray Technology 35
Acrux Enters Into Licensing Agreement With Organon BioSciences 36
Equity Offering 38
Acrux Completes Private Placement Of $19.6 Million 38
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41



List of Tables

Acrux Limited, Key Information 5
Acrux Limited, Key Facts 5
Acrux Limited - Pipeline by Indication, 2013 7
Acrux Limited - Pipeline by Stage of Development, 2013 8
Acrux Limited - Monotherapy Products in Pipeline, 2013 9
Acrux Limited - Combination Treatment Modalities in Pipeline, 2013 10
Acrux Limited - Filed, 2013 11
Acrux Limited - Phase II, 2013 12
Acrux Limited - Phase I, 2013 13
Acrux Limited - Pre-Clinical, 2013 14
Acrux Limited - Pipeline By Route of Administration, 2013 22
Acrux Limited - Pipeline Products By Mechanism of Action, 2013 24
Acrux Limited, Subsidiaries 26
Acrux Limited, Deals Summary 27
KV Pharma Enters Into Licensing Agreement With Acrux 28
Acrux Enters Into A Co-Marketing Agreement With HRA Pharma 29
Acrux Enters Into Co-Marketing Agreement With Vifor Pharma 31
Acrux Enters Into Co-Marketing Agreement With Aspen Pharmacare 32
KV Pharma Expands Licensing Agreement With Acrux 33
Acrux Enters Into Licensing Agreement With Aspen Pharmacare 34
Acrux Enters Into Licensing Agreement With Organon BioSciences For Spray Technology 35
Acrux Enters Into Licensing Agreement With Organon BioSciences 36
Acrux Completes Private Placement Of $19.6 Million 38



List of Figures

Acrux Limited - Pipeline by Indication, 2013 7
Acrux Limited - Pipeline by Stage of Development, 2013 8
Acrux Limited - Monotherapy Products in Pipeline, 2013 9
Acrux Limited - Combination Treatment Modalities in Pipeline, 2013 10
Acrux Limited - Pipeline By Route of Administration, 2013 22
Acrux Limited - Pipeline Products By Mechanism of Action, 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.